芪参益气滴丸对急性冠脉综合征患者冠状动脉介入治疗术后炎症趋化因子水平的影响

目的:观察芪参益气滴丸对急性冠脉综合征(ACS)患者冠状动脉介入治疗(PCI)术后血清炎症趋化因子高敏C反应蛋白(hs-CRP)、1型纤溶酶激活物抑制剂(PAI-1)、内皮素-1(ET-1)水平的影响.方法:选择100例行PCI的ACS患者,随机分为芪参益气滴丸口服+常规治疗(芪参组,n=50)与常规治疗(对照组,n=50),比较两组PCI术前1 d、PCI术后24 h、PCI术后第4周血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1的差异.结果:共有100例完成试验,其中男性70例,女性30例,与对照组比较,PCI术前1 d、PCI术后24 h,芪参组的血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1水平差异无统计学意义(P均＞0.05);芪参组PCI术后4周的高敏C反应蛋白、1型纤溶酶激活物抑制剂和内皮素-1有明显回落(P＜0.05～0.01),差异均有统计学意义;本组间与PCI术前1 d比较,PCI术后24 h及PCI术后4周的血清高敏C反应蛋白、1型纤溶酶激活物抑制剂、内皮素-1浓度均较术前1 d有明显改变(PCI术后24 h为增加,PCI术后4周为回落,P均＜0.01),差异均有统计学意义.结论:芪参益气滴丸可降低ACS患者PCI术后血清炎症趋化因子的水平.

Effect of "Qishen Yiqi Droplet"on Inflammatory Factors in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

Objective:To observe the effect of "Qishen Yiqi Droplet" on serum concentrations of high sensitivity C reactive protein(hs-CRP),plasminogen activator inhibitor-1(PAI-1),endothelin-1(ET-1)in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention (PCI).Methods:A total of 100 consecutive ACS patients ready to receive PCI therapy in our hospital from june 2007 to August 2008 were randomly assigned into two groups:Qishen group,n=50,with Qishen Yiqi Droplet 5.0 g three timee a day+conventional therapy after PCI;and Control group,n=50 with conventional therapy after PCI.The concentrations of hs-CRP,PAI-1 and ET-1were detected and compared 24 hours before PCI,and 24 hours,4weeks after PCI between two groups respectively.Results:There were no obvious differences of hs-CRP,PAI-1 and ET-1 24 hours after PCI in two groups.The levels of hs-CRP,PAI-1,ET-1 were lower in Qishen group than in Control group 4 weeks after PCI (0.219±0.143)ng/dl vs.(0.366±0.132)ng/dl,P<0.001,(104.252±26.038)ng/dl vs.(118.419±28.849)ng/ml,P<0.05,and (37.411±12.977)ng/dl vs.(45.755±12.305)pg/ml,P<0.01,respectively.Conclusion:Qishen Yiqi Droplet could decrease the levels of hs-CRP,PAI-1 and ET-1 in ACS patients who underwent PCI,and it might have the protective role in preventing the neointimal hyperplasia and thrombogenesis after stent implantation.